Search

Charles River Laboratories International Inc

Отворен

СекторЗдравеопазване

203.05 -0.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

199.96

Максимум

203.85

Ключови измерители

By Trading Economics

Приходи

2.9M

56M

Продажби

-27M

1B

P/E

Средно за сектора

592.3

78.892

EPS

2.43

Марж на печалбата

5.529

Служители

18,700

EBITDA

-23M

198M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-1.14% downside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

10B

Предишно отваряне

203.24

Предишно затваряне

203.05

Настроения в новините

By Acuity

100%

0%

362 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Charles River Laboratories International Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.12.2025 г., 15:21 ч. UTC

Печалби

Correction to Home Depot Outlook Headline on Dec. 9

23.12.2025 г., 23:54 ч. UTC

Пазарно говорене

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23.12.2025 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.12.2025 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

St Barbara to Hold Deposit in Escrow

23.12.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23.12.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23.12.2025 г., 20:16 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23.12.2025 г., 19:13 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23.12.2025 г., 18:58 ч. UTC

Пазарно говорене

Gold Has Another Record-Setting Day -- Market Talk

23.12.2025 г., 18:32 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23.12.2025 г., 17:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

23.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

23.12.2025 г., 17:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23.12.2025 г., 16:21 ч. UTC

Пазарно говорене

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23.12.2025 г., 16:15 ч. UTC

Пазарно говорене

Precious Metals Pare Gains -- Market Talk

23.12.2025 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank: Closing Expected Around Mid-January

23.12.2025 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23.12.2025 г., 16:02 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23.12.2025 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Erste Group Bank Receives Green Light for Acquisition in Poland

23.12.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23.12.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Telefonica Doesn't Set Out Financial Details of Divestment

23.12.2025 г., 15:41 ч. UTC

Придобивния, сливания и поглъщания

Telefonica: Deal Will Allow Focus on Core Markets

23.12.2025 г., 15:40 ч. UTC

Придобивния, сливания и поглъщания

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23.12.2025 г., 15:19 ч. UTC

Пазарно говорене

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Charles River Laboratories International Inc Прогноза

Ценова цел

By TipRanks

-1.14% надолу

12-месечна прогноза

Среден 200.55 USD  -1.14%

Висок 225 USD

Нисък 170 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Charles River Laboratories International Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

7

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

117.16 / 144.77Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

362 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat